Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma:Findings From the Phase III MAIA Trial
| Autor: | Peter Mollee, Shaji Kumar, John Fastenau, Jianming He, Katharine S. Gries, Katja Weisel, Cyrille Hulin, Torben Plesner, Jianping Wang, Saad Z. Usmani, Arnaud Jaccard, Aurore Perrot, Ajai Chari, Lionel Karlin, Rian Van Rampelbergh, Kai Fai Ho, Bertrand Arnulf, Thierry Facon, Nizar J. Bahlis, Rachel Kobos, Murielle Roussel, Robert Z. Orlowski, Clarissa M. Uhlar, Hareth Nahi, Karthik Ramasamy, Michel Delforge |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Male PREDNISONE Cancer Research medicine.medical_specialty Time Factors SYMPTOMS IMPACT MEDLINE ANTIBODY DARATUMUMAB BORTEZOMIB Newly diagnosed Transplant ineligible Dexamethasone PALLIATIVE CARE Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Hematologic Malignancy Humans Patient Reported Outcome Measures Lenalidomide Multiple myeloma Aged Pain Measurement Health related quality of life Aged 80 and over UTILITY LENALIDOMIDE Science & Technology business.industry Daratumumab Antibodies Monoclonal ORIGINAL REPORTS Middle Aged medicine.disease DEXAMETHASONE Treatment Outcome Quality of Life MELPHALAN Female business Multiple Myeloma Life Sciences & Biomedicine medicine.drug |
| Zdroj: | Perrot, A, Facon, T, Plesner, T, Usmani, S Z, Kumar, S, Bahlis, N J, Hulin, C, Orlowski, R Z, Nahi, H, Mollee, P, Ramasamy, K, Roussel, M, Jaccard, A, Delforge, M, Karlin, L, Arnulf, B, Chari, A, He, J, Ho, K F, Van Rampelbergh, R, Uhlar, C M, Wang, J, Kobos, R, Gries, K S, Fastenau, J & Weisel, K 2021, ' Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma : Findings From the Phase III MAIA Trial ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 39, no. 3, pp. 227-237 . https://doi.org/10.1200/JCO.20.01370 Journal of Clinical Oncology |
| Popis: | PURPOSE To evaluate the effects of daratumumab, lenalidomide, and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) on patient-reported outcomes (PROs) in the phase III MAIA study. PATIENTS AND METHODS PROs were assessed on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item and the EuroQol 5-dimensional descriptive system at baseline and every 3 months during treatment. By mixed-effects model, changes from baseline are presented as least squares means with 95% CIs. RESULTS A total of 737 transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma were randomly assigned to D-Rd (n = 368) or Rd (n = 369). Compliance with PRO assessments was high at baseline (> 90%) through month 12 (> 78%) for both groups. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item global health status scores improved from baseline in both groups and were consistently greater with D-Rd at all time points. A global health status benefit was achieved with D-Rd, regardless of age (< 75 and ≥ 75 years), baseline Eastern Cooperative Oncology Group (ECOG) performance status score, or depth of response. D-Rd treatment resulted in significantly greater reduction in pain scores as early as cycle 3 ( P = .0007 v Rd); the magnitude of change was sustained through cycle 12. Reductions in pain with D-Rd were clinically meaningful in patients regardless of age, ECOG status, or depth of response. Similarly, PRO improvements were observed with D-Rd and Rd on the EuroQol 5-dimensional descriptive system visual analog scale score. CONCLUSION D-Rd compared with Rd was associated with faster and sustained clinically meaningful improvements in PROs, including pain, in transplant-ineligible patients with newly diagnosed multiple myeloma regardless of age, baseline ECOG status, or depth of treatment response. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|